Table 3.

Plasma acylcarnitine before and after 30 days of carnitine and placebo.

	NGT			IGT placebo			IGT carnitine			IGT placebo			IGT carnitine
	Day 0			Day 0			Day 0			Day 33			Day 33
C0	42.48	±	1.19	39.43	±	1.44	40.77	±	1.57	39.75	±	1.31	50.52	±	1.66a,b,c
C2	5.52	±	0.35	5.95	±	0.36	6.63	±	0.44	6.24	±	0.35	8.28	±	0.61a,b,c
C3	0.44	±	0.02	0.42	±	0.04	0.45	±	0.05	0.47	±	0.03	0.55	±	0.04
C4	0.35	±	0.01	0.31	±	0.01	0.33	±	0.03	0.32	±	0.02	0.34	±	0.02
C5:1	0.01	±	0.00	0.01	±	0.00	0.01	±	0.00	0.01	±	0.00	0.00	±	0.00
C5	0.11	±	0.01	0.09	±	0.01	0.10	±	0.01	0.09	±	0.01	0.10	±	0.01
C4-3OH	0.04	±	0.01	0.04	±	0.01	0.06	±	0.01	0.04	±	0.01	0.04	±	0.01
C6	0.08	±	0.01	0.08	±	0.01	0.08	±	0.01	0.07	±	0.01	0.08	±	0.01
C5OH	0.01	±	0.00	0.01	±	0.00	0.01	±	0.00	0.01	±	0.00	0.01	±	0.00
C8	0.21	±	0.03	0.23	±	0.02	0.25	±	0.03	0.20	±	0.02	0.23	±	0.03
C3 DC	0.06	±	0.01	0.07	±	0.01	0.08	±	0.01	0.06	±	0.01	0.07	±	0.01
C10:1	0.16	±	0.02	0.20	±	0.02	0.22	±	0.03	0.17	±	0.02	0.18	±	0.02
C10	0.25	±	0.03	0.28	±	0.03	0.31	±	0.04	0.24	±	0.03	0.27	±	0.03
C4 DC	0.02	±	0.01	0.04	±	0.01	0.04	±	0.01	0.04	±	0.01	0.06	±	0.01
C5 DC	0.05	±	0.01	0.06	±	0.01	0.06	±	0.01	0.05	±	0.00	0.06	±	0.01
C12:1	0.09	±	0.01	0.10	±	0.01	0.12	±	0.01	0.09	±	0.01	0.11	±	0.01
C12	0.09	±	0.01	0.12	±	0.01	0.13	±	0.02	0.10	±	0.01	0.11	±	0.01
C6 DC	0.02	±	0.00	0.02	±	0.00	0.03	±	0.00	0.02	±	0.00	0.02	±	0.00
C12:1OH	0.03	±	0.01	0.07	±	0.04	0.04	±	0.01	0.03	±	0.01	0.03	±	0.01
C12OH	0.02	±	0.00	0.02	±	0.00	0.02	±	0.00	0.02	±	0.00	0.02	±	0.00
C14:2	0.04	±	0.00	0.05	±	0.00	0.05	±	0.01	0.04	±	0.00	0.04	±	0.01
C14:1	0.09	±	0.01	0.09	±	0.01	0.10	±	0.01	0.09	±	0.01	0.09	±	0.01
C14	0.03	±	0.00	0.04	±	0.00	0.04	±	0.01	0.03	±	0.00	0.03	±	0.00
C8 DC	0.01	±	0.00	0.01	±	0.00	0.01	±	0.00	0.00	±	0.00	0.01	±	0.00
C14:1OH	0.02	±	0.00	0.02	±	0.00	0.02	±	0.00	0.01	±	0.00	0.02	±	0.00
C14OH	0.01	±	0.00	0.01	±	0.00	0.01	±	0.00	0.01	±	0.00	0.01	±	0.00
C16:1	0.03	±	0.00	0.03	±	0.00	0.03	±	0.00	0.03	±	0.00	0.03	±	0.00
C16	0.10	±	0.01	0.10	±	0.01	0.11	±	0.01	0.11	±	0.01	0.11	±	0.01
C10 DC	0.00	±	0.00	0.00	±	0.00	0.00	±	0.00	0.00	±	0.00	0.00	±	0.00
C16:1OH	0.01	±	0.00	0.01	±	0.00	0.01	±	0.00	0.01	±	0.00	0.01	±	0.00
C16OH	0.00	±	0.00	0.00	±	0.00	0.00	±	0.00	0.00	±	0.00	0.00	±	0.00
C18:2	0.04	±	0.00	0.04	±	0.00	0.04	±	0.00	0.04	±	0.00	0.04	±	0.00
C18:1	0.10	±	0.01	0.11	±	0.01	0.11	±	0.01	0.11	±	0.01	0.11	±	0.01
C18	0.04	±	0.00	0.03	±	0.00	0.04	±	0.00	0.04	±	0.00	0.04	±	0.00
C18:2OH	0.00	±	0.00	0.00	±	0.00	0.00	±	0.00	0.00	±	0.00	0.00	±	0.00
C18:1OH	0.00	±	0.00	0.00	±	0.00	0.00	±	0.00	0.00	±	0.00	0.00	±	0.00
C18OH	0.00	±	0.00	0.00	±	0.00	0.00	±	0.00	0.00	±	0.00	0.00	±	0.00

^asignificantly different from day 0.

^bdifferent from IGT on placebo at day 33,.

^csignificantly different from NGT day 33. Post-hoc analysis were performed and Bonferroni correction was applied to correct of multiple testing after a significant time*treatment effect by mixed model repeated measures ANOVA. To prevent multiple testing, the other single acylcarnitine species are displayed but not tested for statistical significance.

Data are expressed as mean ± SEM. Statistical significance of the differences in C0 and C2 were tested as described.